Targeting HDAC6 and its novel E3 ligase activity: A dual-strategy for cardiovascular therapy
- 2 June 2026
- journal article
- review article
- Published by Elsevier in Ageing Research Reviews
- Vol. 120, 103200
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82170370)
- National Natural Science Foundation of China (81770381)
This publication has 119 references indexed in Scilit:
- Histone deacetylase 6 inhibition attenuates pathological cardiac hypertrophy by promoting autophagy through MAP1LC3B ubiquitinationThe Journal of Pathology, 2025
- Maintenance of Cardiac Microenvironmental Homeostasis: A Joint Battle of Multiple CellsJournal of Cellular Physiology, 2024
- Knockdown of HDAC6 alleviates ventricular remodeling in experimental dilated cardiomyopathy via inhibition of NLRP3 inflammasome activation and promotion of cardiomyocyte autophagyCell Biology and Toxicology, 2022
- Myocardial ischemia‐reperfusion induced cardiac extracellular vesicles harbour proinflammatory features and aggravate heart injuryJournal of Extracellular Vesicles, 2021
- SGLT2 inhibitors: a focus on cardiac benefits and potential mechanismsHeart Failure Reviews, 2021
- Zebrafish hhatla is involved in cardiac hypertrophyJournal of Cellular Physiology, 2020
- Telomere transcription in ageingAgeing Research Reviews, 2020
- Doxorubicin-induced chronic dilated cardiomyopathy—the apoptosis hypothesis revisitedJournal of Molecular Medicine, 2016
- The physiological role of cardiac cytoskeleton and its alterations in heart failureBiochimica et Biophysica Acta (BBA) - Biomembranes, 2014
- Regulation of fetal gene expression in heart failureBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013